Project Grant R01AI202702
Award Date 8/10/26
Completion Date 7/31/31
Dollars Obligated $984K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21287, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Massachusetts Medical School $460,625 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immune mechanisms underlying BCG vaccine protection against tuberculosis. The research uses Collaborative Cross mouse strains to identify immune signatures associated with vaccine-induced TB protection across genetically diverse host populations. The study focuses on a...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $256,000 will develop Recombinant BCG as a novel immunoadjuvant for viral infections. The awardee, Oncosting LLC located in Baltimore, Maryland, will optimize media and lyophilization manufacturing of BCG-STING, evaluate its immunological effects as an adjuvant for H1N1 influenza vaccination, and assess its protective effects as an H1N1 vaccine adjuvant. By adding stimulator of...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $810,282 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate combination adjuvants that target trained immunity and the TH1/TH17 immune axis to enhance vaccine efficacy against tuberculosis and other infectious diseases. The research addresses the variable protective efficacy of the currently licensed TB vaccine, Mycobacterium bovis BCG (0–80%...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded Beth Israel Deaconess Medical Center, Inc. $1,296,750 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel trivalent adjuvanted tuberculosis vaccine. The research will characterize and advance a trivalent TB vaccine candidate consisting of three antigens—PPE20 (RV1387), ESXG (RV0287), and...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $1,229,998 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel TH17-inducing mucosal tuberculosis vaccine. The research advances preclinical development of NETB-EA, a nanoemulsion-based vaccine candidate that delivers immunodominant Mycobacterium tuberculosis antigens (AG85B and ESAT6) via intranasal vaccination to induce T helper type 17 cell...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $2.576 million on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct integrated research targeting the cGAS-STING pathway in autoimmune and inflammatory disease. The program assembles a team with complementary expertise in immunology, structural biology, medicinal chemistry, proteomics, and pharmacology to investigate the...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Research Institute $1,033,950 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a tuberculosis vaccine regimen optimized to induce lung-resident T cells. The project, titled "A Prime-Pull TB Vaccine Regimen Optimized to Induce Lung-Resident T Cells," focuses on identifying and testing mRNA-lipid nanoparticle vaccine candidates designed to generate...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin - Madison $717,003 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and assess protective mRNA vaccines against tuberculosis. The project focuses on evaluating the safety, immunogenicity, and protective efficacy of QRNA, a novel mRNA vaccine delivered via QUILA-DOTAP (QTAP), a lipid nanoparticle adjuvant designed for stable mRNA delivery across...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a $3.14 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 19, 2025, with a completion date of August 31, 2029. This award supports basic biomedical research investigating macrophage senescence as a driver of granuloma failure and progression to necrosis in tuberculosis (TB) and TB/HIV co-infection. The...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $439,375 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate S protein as a vaccine candidate against Group A Streptococcus. The funded research aims to advance S protein as a protective vaccine against GAS, addressing a pathogen responsible for an estimated 700 million infections and half a million deaths annually....